Toxic shock syndrome: Difference between revisions

From IDWiki
mNo edit summary
No edit summary
 
Line 1: Line 1:
  +
== Background ==
 
* Severe septic shock caused by certain bacterial infections, primarily ''[[Staphylococcus aureus]]'' and ''[[Streptococcus pyogenes]]''
 
* Severe septic shock caused by certain bacterial infections, primarily ''[[Staphylococcus aureus]]'' and ''[[Streptococcus pyogenes]]''
** Caused by superantigens, which non-specifically activate T-cells
+
** Caused by superantigens, which non-specifically activate a massive number of T-cells
 
*Similar syndrome can be caused by toxin production of [[Clostridial toxic shock syndrome|''Clostridium sordelli'']]
 
*Similar syndrome can be caused by toxin production of [[Clostridial toxic shock syndrome|''Clostridium sordelli'']]
   
  +
== Criteria ==
 
{| class="wikitable"
 
{| class="wikitable"
 
! Criteria
 
! Criteria
Line 56: Line 58:
 
|
 
|
 
|}
 
|}
  +
  +
== Management ==
  +
{| class="wikitable"
  +
!
  +
!First-Line
  +
!Beta-lactam Allergy
  +
!Notes
  +
|-
  +
|[[Streptococcus pyogenes]]
  +
|[[Penicillin G]] and [[clindamycin]]
  +
|[[Macrolide]] or [[fluoroquinolone]], and [[clindamycin]]
  +
|Macrolide and fluoroquinolone resistance increasing
  +
|-
  +
|MLS-resistant [[Streptococcus pyogenes]]
  +
|[[Penicillin G]], and [[vancomycin]] or [[teicoplanin]]
  +
|[[Vancomycin]] or [[teicoplanin]]
  +
|Macrolide resistance associated with clindamycin resistance
  +
|-
  +
|Methicillin-susceptible [[Staphylococcus aureus]]
  +
|[[Cloxacillin]] or [[nafcillin]] or [[cefazolin]], and [[clindamycin]]
  +
|[[Clarithromycin]] and [[clindamycin]]
  +
|
  +
|-
  +
|Methicillin-resistant [[Staphylococcus aureus]]
  +
|[[Clindamycin]] or [[linezolid]], and [[vancomycin]] or [[teicoplanin]]
  +
|
  +
|
  +
|-
  +
|Glycopeptide resistant or intermediate [[Staphylococcus aureus]]
  +
|[[Linezolid]] and [[clindamycin]] (if susceptible)
  +
|
  +
|Incidence increasing. Geographical patterns highly variable
  +
|}
  +
  +
== Further Reading ==
  +
  +
* Gram-positive toxic shock syndromes. ''Lancet Infect Dis''. 2009;9(5):281-290. doi: [https://doi.org/10.1016/S1473-3099(09)70066-0 10.1016/S1473-3099(09)70066-0]
   
 
[[Category:Infectious syndromes]]
 
[[Category:Infectious syndromes]]

Latest revision as of 10:34, 22 November 2022

Background

Criteria

Criteria Staphylococcal Streptococcal
Confirmed hypotension + fever + rash + desquamating + 3 or more other hypotension + 2 or more other
Hypotension SBP ≤90 mmHg SBP ≤90 mmHg
Fever temp ≥38.9ºC
Skin diffuse macular erythroderma followed by desquamation generalized erythematous macular rash that may desquamate
GI n/v/d at onset
Resp ARDS
MSK myalgia ± CK ≥2x ULN soft-tissue necrosis (e.g. nec.fasc)
Mucosa hyperemia of any mucosa
Nephro Creatinine ≥2x ULN, or
pyuria without UTI
Creatinine ≥177 or ≥2x ULN or ≥2x baseline
Hepatic bili/ALT/AST ≥2x ULN ALT/AST/bili ≥2x ULN or ≥2x baseline
Heme thrombocytopenia <100 thrombocytopenia ≤100, or
DIC (INR/fibrinogen/D-dimer)
CNS altered LOC without focal signs

Management

First-Line Beta-lactam Allergy Notes
Streptococcus pyogenes Penicillin G and clindamycin Macrolide or fluoroquinolone, and clindamycin Macrolide and fluoroquinolone resistance increasing
MLS-resistant Streptococcus pyogenes Penicillin G, and vancomycin or teicoplanin Vancomycin or teicoplanin Macrolide resistance associated with clindamycin resistance
Methicillin-susceptible Staphylococcus aureus Cloxacillin or nafcillin or cefazolin, and clindamycin Clarithromycin and clindamycin
Methicillin-resistant Staphylococcus aureus Clindamycin or linezolid, and vancomycin or teicoplanin
Glycopeptide resistant or intermediate Staphylococcus aureus Linezolid and clindamycin (if susceptible) Incidence increasing. Geographical patterns highly variable

Further Reading